HCP Tiering: How to Prioritize Prescribers Without Overfitting to Volume

Tiering is the quiet decision that drives most HCP budgets. Once a prescriber is labeled Tier 1, they get more rep calls, more email, a higher media frequency cap, and priority in every audience file. If the tier is wrong, the whole plan inherits the mistake. This article is part of the HCP engagement series and focuses on how to build tiers that still make sense a year later.

What HCP tiering usually looks like

The standard approach sorts prescribers in the brand's market by volume (TRx or NRx in the therapeutic class, often from a syndicated Rx data source) and splits them into ten deciles. Decile 10 writes the most. Teams then group deciles into tiers: say, deciles 8 to 10 as Tier 1, 5 to 7 as Tier 2, and so on.

Deciles have one strong advantage: they are already in the CRM and everyone understands them. They have three weaknesses that matter for engagement.

• They measure history, not potential. A decile 10 HCP writing almost entirely your brand has little room to grow. A decile 6 HCP with a large untreated patient pool may have much more.
• They miss new writers. A recently credentialed specialist or a new practice may have no volume yet.
• They are blind at launch. A new mechanism has no brand history. Market or class deciles help, but they assume the new product will be prescribed like the old ones.

Potential vs. historic volume

The fix is to score two things separately and combine them. Historic volume says who already writes in the class. Potential estimates what they could write: patient pool size (from claims or diagnostic data where available and permitted), share of class still on competitors, and practice growth.

A simple hypothetical blend: score each HCP 1 to 5 on class volume, 1 to 5 on headroom (inverse of brand share), and 1 to 5 on patient potential, then weight 40%, 30%, and 30%. An HCP scoring 5, 1, 2 gets 0.4 x 5 + 0.3 x 1 + 0.3 x 2 = 2.9. One scoring 3, 4, 4 gets 1.2 + 1.2 + 1.2 = 3.6. The second HCP outranks the first, even though their volume decile is lower. Whether those weights are right is an empirical question, which is the point of testing.

Access changes the channel, not the priority

Access is often treated as a tier input: no-see HCPs get pushed down. I would keep access separate. A high-potential prescriber who refuses rep visits is still high potential. What changes is the channel. That HCP should get more weight in programmatic, email, and point of care, because the field cannot carry the message. Mixing access into the tier score hides that decision. The article on coordinating HCP outreach across channels covers how channel weight shifts for no-see segments.

New writers and launch brands

New writers deserve their own flag. An HCP who wrote their first two scripts of your brand last month is at the most persuadable point they will ever be. A rule like "first-time writers get Tier 1 treatment for 90 days, then re-tier" is easy to implement and often more useful than any model. For launches, start with market deciles plus patient potential, then re-tier monthly in the first year as brand data accumulates. The drug launch media plan article covers the pre-launch to year one sequence.

How tiers should change media weight and frequency

1. Decide the lever for each tier. Tier 1 might get field plus programmatic plus email; Tier 3 might get programmatic reach only.
2. Set frequency ceilings by tier, not one cap for everyone. For example (illustrative), Tier 1 up to 8 exposures per week across channels, Tier 2 up to 5, Tier 3 up to 3. The frequency cap guide covers how to set and revisit these.
3. Weight bids or budgets, not just audiences. Putting all tiers in one line item with one bid lets the cheapest inventory win, which usually means lower tiers get most of the impressions.
4. Hold out a slice of each tier. A small holdout per tier tells you whether Tier 1 actually responds more to media than Tier 3. Sometimes it does not, because Tier 1 is already saturated by the field.
5. Re-tier on a schedule. Quarterly is common. Keep the old tier on each record so you can see movement.

Where tiering goes wrong

The most common failure is circular evidence. Tier 1 gets the most media, Tier 1 writes the most, so the team concludes Tier 1 responds best to media. Of course it writes the most. That is why it is Tier 1. Only a within-tier comparison (exposed vs. held out) can say anything about response. The second failure is building tiers so granular that each cell has 40 HCPs, which makes media delivery and measurement both unreliable. Fewer, larger tiers are easier to plan and read. The guide to building an NPI target list covers sizing.

Practical takeaway

Pull your current Tier 1 list and add one column: brand share of class volume. If a large share of Tier 1 HCPs are already writing mostly your brand, you have found budget that may be better spent on high-potential prescribers in Tiers 2 and 3. Test that shift with a holdout before making it permanent.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.